RxDoctor Payments Data

Kimberly Hornes

Family · Fond du Lac, WINPI 1861046591

Payments from drug & device makers

What this record shows

6 manufacturers reported payments, led by Boston Scientific at 53.0% of the total. Reporting peaked in 2022 at $4,685 and has fallen 90.0% since, to $471 in 2025. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,853in general payments, 2019–2025

Across 60 payments — averaging $97.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$2K
  • Edwards Lifesciences$125
  • Boehringer Ingelheim$125
  • Novartis$42
  • Heartflow, Inc.$21

What the payments were for

  • Travel & lodging$3,35457%
  • Food & beverage$2,49943%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,853 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$15,730
Medicare patients
162
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban146$156,047
JardianceEmpagliflozin60$55,731
XareltoRivaroxaban34$35,050
BrilintaTicagrelor24$22,951
Repatha SureclickEvolocumab12$15,079
Metoprolol Succinate471$8,322
Atorvastatin Calcium398$5,955
ClopidogrelClopidogrel Bisulfate244$3,000
Bumetanide95$2,782
Potassium Chloride102$2,772
Losartan Potassium162$2,178
Ranolazine ErRanolazine19$2,127
Isosorbide Mononitrate ErIsosorbide Mononitrate166$2,102
Rosuvastatin Calcium153$2,017
Furosemide295$1,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$125$55,73160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.

Other family in Fond du Lac

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →